News | News By Subject | News by Disease News By Date | Search News

Hemophilia A News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Genentech (RHHBY)'s Hemophilia Blockbuster Contender Hits Phase III Goals, But Questions Remain     6/27/2017
Pfizer (PFE) Makes a $545 Million Deal With Another Bay Area Biotech, Sangamo (SGMO)     5/12/2017
Why All Eyes Will be on Alnylam (ALNY) and Any Updates of Its APOLLO Phase III Trial This Friday     5/11/2017
Genentech (RHHBY) Shows Off Late-Stage Hemophilia A Data     4/17/2017
One Death in the HAVEN 1 Trial Complicates Roche (RHHBY)’s Entry into the Hemophilia A Market     3/13/2017
Roche (RHHBY) Reports Death in Phase III Hemophilia Study     2/27/2017
Roche (RHHBY) Takes a Win as Emicizumab Hemophilia Drug Succeeds in Phase III     12/22/2016
Sources Reveal Biogen (BIIB) is Exploring Sale of Hemophilia Assets     4/12/2016
FDA Gives Thumbs Up to Bayer (BAY)'s Hemophilia A Drug Kovaltry     3/17/2016
FDA Green Lights Octapharma USA's NUWIQ for Hemophilia A     9/15/2015
Genentech (RHHBY)’s Hemophilia A Drug Gets Breakthrough Designation in Potential $11 Billion Market     9/10/2015
Biogen Idec (BIIB) Will Be Hiring in R&D After Around 20 Employees Leave Following Review     3/17/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014

News from Around the Web

Press Releases
Sangamo (SGMO) And Pfizer (PFE) Announce First Patient Receives Treatment In Phase I/II Clinical Trial Evaluating SB-525 Investigational Gene Therapy For Hemophilia A     8/25/2017
Genentech (RHHBY)'s Hemophilia Contender Wins Priority Review From The FDA     8/24/2017
Chugai Pharma's Emicizumab Receives Priority Review Designation By FDA For Hemophilia A With Inhibitors     8/24/2017
Octapharma USA Announces FDA Approval Of NUWIQ New Product Strengths, Expanding Hemophilia A Patient Treatment Options     8/22/2017
Spark Therapeutics (ONCE) Unveils Encouraging Hemophilia A Data     8/3/2017
BioMarin (BMRN) Announces Plans To Progress Both The 6e13vg/Kg And 4e13 Vg/Kg Doses Of BMN 270, Its Investigational Gene Therapy For Hemophilia A, Into Phase III Studies     8/3/2017
Sernova Corp. (SVA.TO)-HemAcure Consortium Announce Significant Progress In Development Of ‘First In World’ Regenerative Medicine Therapy For Treatment Of Hemophilia A Patients     7/24/2017
BioMarin (BMRN)'s Investigational Gene Therapy For Hemophilia A At 6e13 Vg/Kg Dose Maintains Average Factor VIII Levels Within Normal Range For Over One Year     7/11/2017
Octapharma AG Symposium At ISTH Berlin Supports Progress In Lifelong Treatment Of High-Risk Patients With Von Willebrand Disease (VWD) And Haemophilia A     7/11/2017
CSL Behring Release: New Findings Show AFSTYLA Provides Long-Lasting Efficacy Without Increased Product Consumption For Prophylactic And On-Demand Treatment Of Hemophilia A     7/10/2017
ISTH 2017, Berlin: Octapharma AG Presents Exciting Nuwiq Data In Previously Untreated Patients And Demonstrates Real-Life Value Of Personalised Prophylaxis For Hemophilia A     7/10/2017
Shire (SHPG) Submits Investigational New Drug Application To FDA For Gene Therapy Candidate SHP654 For Treatment Of Hemophilia A     7/6/2017
Genentech (RHHBY)’s Emicizumab Showed Positive Results In Phase III Studies (HAVEN 1 And HAVEN 2) In Hemophilia A With Inhibitors     6/26/2017
MacroGenics (MGNX) Presents Updated Data From Phase I Study Of MGD010 At Annual European Congress Of Rheumatology (EULAR 2017)     6/19/2017
Bioverativ (BIVV) Announces FDA Acceptance Of Investigational New Drug Application For BIVV001 To Treat Hemophilia A     6/12/2017